Anlon Healthcare share price
NSE: AHCLBSE: 544497Pharmaceuticals & BiotechnologySmall Cap
Last close ₹25.56up ₹1.21 (4.97%)BSE ₹25.55
Share price at the NSE close on 23 Oct 2026. Previous close ₹24.35.
52-week range of traded prices to 23 Oct 2026
₹10.37Low, 2 Mar 2026₹37.24High, 30 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,359 Cr1,681st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 46.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 30 Jul 2026
- 13.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 18.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 67,35,80547.9% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 30 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹88 Crup 72.07%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹8.28 Crdown 25.20%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 9.5%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Mar 2026Filed 29 May | Jun 2026Filed 30 Jul |
|---|---|---|
| Revenue | 50.9 | 87.6 |
| Net profit | 11.1 | 8.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 21.8% | 9.5% |
Consolidated. The 2 quarters from Mar 2026, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing & Sale of Active Pharmaceutical Ingredients, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 91% of 235 trading days since Nov 2025.
LowestHighest
Its median3.6Industry median2.8
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 6,960 | 0.05% | ₹0.02 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 3,281 | 0.05% | ₹0.01 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Anlon Healthcare in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Hester BiosciencesHESTERBIO | 1,750 | 12.8 | 4.9 | 22.3 | +4.1% | +262.2% | 40.4% | 11.7% | 0.53% |
 NGL Fine-ChemNGLFINE | 1,634 | 28.6 | 5.0 | 20.6 | +40.5% | – | 18.7% | 14.5% | 0.07% |
 Amrutanjan Health CareAMRUTANJAN | 1,410 | 26.1 | 3.8 | 18.7 | +10.7% | −1.0% | 15.5% | 18.0% | 1.00% |
 Jagsonpal PharmaceuticalsJAGSNPHARM | 1,399 | 30.8 | 5.1 | 21.2 | +3.9% | −25.2% | 17.6% | 18.8% | 1.89% |
 Fermenta BiotechFERMENTA | 1,326 | – | 3.3 | 15.5 | −3.2% | – | – | 13.5% | 0.83% |
 KopranKOPRAN | 1,190 | 47.6 | 2.2 | 21.8 | +12.0% | −28.4% | 4.8% | 6.2% | 1.22% |
 Bharat ParenteralsBPLPHARMA | 1,165 | – | 3.6 | 122.9 | −11.2% | – | – | −5.2% | 0.06% |
 Bajaj HealthcareBAJAJHCARE | 1,052 | 51.0 | 1.9 | 11.5 | +14.2% | −55.0% | 4.0% | 10.2% | 0.48% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
13 Oct · Board meeting
Sep 2026
29 Sep · Board meeting
21 Sep · Disclosure of material issue
21 Sep · Disclosure of material issue
17 Sep · Legal
The exchange asked on 16 Sep 2026
Anlon Healthcare share price by year
Each calendar year to 2025.Anlon Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 15.10 | – | 16.86 | 9.10 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 3 Sep 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 24.35 | 25.56 | 23.14 | 25.56 | 24.24 | 67,35,805 | 47.9% |
| 22 Oct 2026 | 25.30 | 25.74 | 24.35 | 24.35 | 24.67 | 64,96,159 | 53.9% |
| 21 Oct 2026 | 26.97 | 27.00 | 25.63 | 25.63 | 25.84 | 37,40,841 | 51.9% |
| 19 Oct 2026 | 27.15 | 27.78 | 26.20 | 26.97 | 27.10 | 77,08,078 | 41.0% |
| 16 Oct 2026 | 27.41 | 28.56 | 26.22 | 26.85 | 27.18 | 1,15,73,707 | 38.6% |
| 15 Oct 2026 | 28.20 | 28.46 | 27.59 | 27.59 | 27.78 | 46,53,511 | 52.0% |
| 14 Oct 2026 | 30.97 | 30.99 | 29.04 | 29.04 | 29.63 | 1,21,63,347 | 47.3% |
| 13 Oct 2026 | 30.50 | 30.98 | 28.27 | 30.56 | 29.56 | 2,18,25,288 | 37.2% |
| 12 Oct 2026 | 29.51 | 29.51 | 28.69 | 29.51 | 29.33 | 1,07,71,809 | 51.7% |
| 9 Oct 2026 | 26.60 | 28.11 | 25.51 | 28.11 | 27.06 | 2,04,27,857 | 37.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 24 Apr 2026 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 24 Apr 2026 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- Legal name
- Anlon Healthcare Limited
- NSE symbol
- AHCL
- BSE code
- 544497
- ISIN
- INE0Y8W01025
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2025
- Face value
- ₹2
- CIN
- U24230GJ2013PLC077543
- Corporate identity number, the registrar of companies' code for it